Eric Lefkofsky’s Involvement with Tempus

When he started Groupon, Eric Lefkofsky aimed at saving money for his customers and helping them to travel across the globe but eventually made a fortune from the company. He subsequently opened a new startup known as Tempus which is aimed at helping people better their health. The organization uses genomic sequencing to help physicians offer better treatment to cancer patients. Tempus has been organizing for series of fundraising and has been able to raise about $70 million from New Enterprise Associates and Revolution growth. The amount of money constitutes the $130 million that Tempus has raised since Eric Lefkofsky first co-founded it barely two years ago. He co-founded it together with his friend and business partner.

Speculations have it that Tempus is valued at about $700 million. For every fundraising round that has been conducted in support of Tempus and its course, Eric Lefkofsky and his co-founder have been investing as individuals. They are indeed the largest investors of the institution. In an interview conducted by Crain’s Chicago Business, Eric Lefkofsky revealed that he would invest up to a total of $100 million in the business. Tempus is not the first company that New Investors Associates and Revolution growth are funding. They have previously supported a revolutionary food chain Known as Sweetgreens, a genome organization known as 23AandMe, as well as a trading app known as Robinhood.

About three years ago, one of the close relatives of Eric Lefkofsky was diagnosed with cancer. During the treatment process, he observed that there lacked an up to date way of collecting data. It is this situation that motivated him to start up Tempus. Tempus has now made it possible to bring together large quantities of clinical data from cancer patients to help physicians offer better personalizes treatment.

Eric Lefkofsky was born in the year 1969 to a structural engineer. He attended the University of Michigan. Later, he earned his Juris Doctor from University of Michigan School of law. At one time, Mr. Lefkofsky was selling carpets at the University of Michigan. Even after starting up Tempus, he remained the chief executive of Groupon.

Jim Tananbaum Welcomes Experienced Venture Partner to Foresite Capital

Foresite Capital has had a busy beginning to their 2017 year. The medical research growth equity firm has been bringing on high profile, big name talent to their team. New addition Jim Tananbaum, M.D, was named to the Forbe’s Midas List of Top Tech Investors for an incredible third straight time. On the heels of his successful month the company decided to add another venture partner to the team, Dr. Molly He. News of Dr. He’s addition to the team was welcomed and immediately receptive from high ranking members of Foresite Capital.

The first person to welcome Dr. He to the team was Dr. Jim Tananbaum himself. Dr. Tananbaum spoke in a statement regarding Dr. He where he regarded her as one of the most respected of scientific researchers in the field of next generation sequencing. Dr. Tananbaum regaled her experience in the field of genomics as well as drug development and considered her also a remarkable leader with an extensive track record as both a leader and a team member. He finished off his statement by calling her ‘an invaluable resource to Foresite’ as they ‘continue to expand and diversify our portfolio of transformational companies.’

According to Fierce Biotech, Dr. Tananbaum’s words are more than just fluff to welcome a new employee. Dr. Tananbaum himself established Foresite Capital and he has a total of 25 years’ worth of leadership within the industry. Tananbaum’s been an active investor in the healthcare field while focusing on the different ways you can build and develop franchise healthcare businesses. Dr. Jim Tananbaum also helped to co-found GelTex Pharmaceuticals which managed to bring two different drugs to the market before being bought out for a jaw dropping $1.6 billion.

Of course, Dr. He would not be invited to the team without her own skills evidenced and on display. Dr. He previously worked as the senior director of scientific research over at Illumina where she served the company for years. Before Illumina Dr. He had spent ten years in the pharmaceutical industry as well as in a leadership role over at Pacific Biosciences. Needless to say, Dr. He will be welcomed with open arms at Foresite Capital. More details can be found on LinkedIn.

Read more: https://www.researchgate.net/profile/Jim_Tananbaum